NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant

Next deadline: Oct 10, 2022 (Full proposal)

Later deadlines: Jan 13, 2023 (Letter of inquiry), Feb 13, 2023 (Full proposal), May 12, 2023 (Letter of inquiry), Jun 12, 2023 (Full proposal)

Grant amount: Up to US $275,000

Fields of work: Cancer/Oncology

Applicant type: Government Entity, Indigenous Group, Nonprofit, For-Profit Business

Funding uses: Research

Location of project: Preferred: United States Other eligible locations: Anywhere in the world

Location of residency: Preferred: United States Other eligible locations: Anywhere in the world

Overview:

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed September 23, 2022 and last updated July 15, 2022